Bal, OznurArslan, Ulku YalcintasDurnali, AyseUyetrk, UmmugulDemirci, AyseTastekin, DidemEkinci, Ahmet2024-09-252024-09-2520151107-0625https://hdl.handle.net/20.500.12491/12483Purpose: To evaluate the impact of progesterone receptor (PR) status on estrogen receptor (ER)-positive and HER2-negative breast cancer. Methods: A total of 1673 operable breast cancer patients, diagnosed from June 1984 to June 2 Oil were retrospectively reviewed and 400 patients with ER-positive and HER2-negative tumors were identified and evaluated. ER-positive and HER2-negative patients were classified into two groups: group A: ER+/PR-/HER2- And group B : ER+/PR+/HER2- According to PR status. Results: Median follow-up was 14.2 years (range 10.1-18.2). The ratio of postmenopausal patients was significantly higher in group A (68.2%, p=0.015). Grade 1 tumor and stage I disease were significantly higher in group B (15%, p=0.007 and 15%, p=0.005, respectively). Mean overall survival (OS) and disease free survival (DFS) were significantly better in group B (15.3±1.5 years vs 8.7±0.8 years, p=0.032; 10.5±1.6 years vs 5.7±0.5 years, p=0.022) as compared with group A Relative risk for recurrence and death were two-fold higher in group A (p=0.05 and p=0.01, respectively). Conclusion: PR status exerts a significant impact on prognosis ofER+/HER2- breast cancer.eninfo:eu-repo/semantics/closedAccessBreast cancerEstrogen receptorHER2Progesterone receptorPrognosisArticle2012834257782922-s2.0-84928696434Q3